Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors

Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pat...

Full description

Bibliographic Details
Main Authors: Ciara C. O'Sullivan, Dominic H. Moon, Elise eKohn, Jung-Min eLee
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-02-01
Series:Frontiers in Oncology
Subjects:
solid tumors
PARP inhibitor
BRCAmutation
BRCAlike
DNA damge repair pathway
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00042/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00042/full

Similar Items